A new treatment for lung cancer that has spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a confirmed diagnosis of non-small cell lung cancer (NSCLC) that is not squamous (a specific cell type).
- Your cancer must have spread to the brain, and you must have at least one brain tumor that has not been treated with radiation or has grown after radiation.
- You cannot have had any previous cancer treatment for advanced or metastatic disease, and you must not have certain genetic changes (like EGFR or ALK) in your tumor.
- You should have a performance status of 0 or 1 (meaning you are fully active or able to do light work).
- You need to have adequate organ function (kidneys, liver, blood counts) and no other serious medical conditions (like uncontrolled heart disease, active infections, or lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using focused ultrasound to temporarily open the brain’s blood barrier—plus standard immune therapy—can better treat non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to help medicines reach the brain tumor spots more effectively, while still using the usual lung cancer treatment.
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.